A Phase 2b/3 Trial of SJP-002C.
Latest Information Update: 07 Nov 2025
At a glance
- Drugs SJP-002C (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 07 Nov 2025 New trial record
- 26 Sep 2025 According to Sen Jam Pharmaceutical media release, company announced the successful completion of the final development submission batches of SJP-002C and finalized the Chemistry, Manufacturing, and Controls (CMC) package, meeting FDA standards and positioning the program for Phase 2b/3 clinical trials.
- 26 Sep 2025 According to Sen Jam Pharmaceutical media release, company is now positioned to begin the next phase of clinical testing.